Active, not recruitingNCT04515524

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

Studying Retinopathy of prematurity

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Regeneron Pharmaceuticals
Principal Investigator
Clinical Trial Management
Regeneron Pharmaceuticals
Intervention
Non-Interventional(other)
Enrollment
100 enrolled
Eligibility
5 years · All sexes
Timeline
20212026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04515524 on ClinicalTrials.gov

Other trials for Retinopathy of prematurity

Additional recruiting or active studies for the same condition.

See all trials for Retinopathy of prematurity

← Back to all trials